Cognitive rehabilitation among long COVID patients using vibratory and auditory treatment (VAT) is linked to BDNF.

ingentiumby ingentium

In Long Covid Literature.

Publication date: Jun 24, 2026

Cognitive dysfunction occurs in around 40% of long COVID (LC) patients, and in many cases appears second only to fatigue in prevalence. Vibratory and auditory treatment (VAT) within the gamma range has demonstrated improvements in symptoms associated with cognition and fatigue. In this open-label pilot study, we tested the effects of VAT on measures of cognition and fatigue in LC. Twenty patients were randomly divided into a treatment and a control group. Symptoms were monitored remotely through mobile apps and in-person visits before and after the treatment period. The treatment group received a device generating 40 Hz of VAT to take home and use every day from Monday to Friday for 4 weeks (i. e., 20 sessions over 28 days), whereas the control group did not use any device but followed the same data collection procedures. This study found that after 4 weeks of VAT, participants with LC exhibited increased performance in selective attention and response inhibition, an increased amount of circulating brain-derived neurotrophic factor (BDNF), and a reduced resting heart rate. We propose that VAT may be a useful rehabilitative tool for LC as well as other targeted populations that seek improvements in cognition or general health but are compromised immunologically or physically.

Open Access PDF

Concepts Keywords
Apps cognition
Friday COVID
Neurotrophic Long COVID
Pilot sound
Rehabilitative vibroacoustic

Semantics

Type Source Name
disease MESH long COVID
disease MESH Cognitive dysfunction
disease MESH fatigue
pathway REACTOME Reproduction
disease MESH COVID 19
disease MESH syndrome
disease MESH infection
disease MESH dysautonomia
disease MESH postural orthostatic tachycardia syndrome
disease MESH brain fog
drug DRUGBANK Guanosine
disease MESH anxiety
disease MESH inflammation
disease MESH viral infections
disease MESH cognitive symptoms
disease MESH Alzheimer’s disease
drug DRUGBANK Nitric Oxide
disease MESH pain
disease MESH fever
disease MESH included
disease MESH hearing impairment
disease MESH epilepsy
disease MESH seizures
drug DRUGBANK Dapsone
disease MESH DDS
disease MESH Headache
disease MESH Joint pain
disease MESH Muscle pain
disease MESH Sleep disorder
disease MESH Tinnitus
disease MESH Dizziness
disease MESH Double vision
disease MESH Tachycardia
disease MESH symptom exacerbation
disease MESH Tremor
disease MESH Cough
disease MESH Confusion
disease MESH Chest pain
disease MESH Orthostatic intolerance
disease MESH Numbness
disease MESH Chills
disease MESH Hives
disease MESH Back pain
disease MESH Sore throat
disease MESH Nerve pain
disease MESH Indigestion
drug DRUGBANK Isoxaflutole
disease MESH Rash
disease MESH Hair loss
disease MESH weight gain
disease MESH diarrhea
disease MESH chronic pain
disease MESH fibromyalgia
disease MESH Nausea
disease MESH Vertigo
drug DRUGBANK Albendazole
drug DRUGBANK Edetic Acid
disease MESH learning disabilities
disease MESH injury
drug DRUGBANK Penciclovir
pathway KEGG Viral replication
pathway REACTOME Immune System
disease MESH frailty
disease MESH severe acute respiratory syndrome
disease MESH Dis
drug DRUGBANK Carboxyamidotriazole
disease MESH chronic diseases
drug DRUGBANK Vorinostat
disease MESH memory deficits
disease MESH mental illness
drug DRUGBANK Ethanol
disease MESH neuroinflammation
disease MESH cytokine storm
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH hepatitis
disease MESH Poh
disease MESH traumatic brain injury
disease MESH myocardial infarction
disease MESH sepsis

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *